Lice Treatment Market Size & Share 2024 to 2032

Lice Treatment Market Size

Lice Treatment Market size was valued at USD 1 billion in 2023 and is expected to exhibit growth of 6.5% from 2024 to 2032. The rising prevalence of lice infestations is a significant factor propelling the market growth.

Lice infestations are highly contagious, particularly in settings where people are in close contact, such as schools, childcare facilities, camps, and households. The ease of transmission through direct head-to-head contact or sharing of personal items, such as hats, combs, and clothing, increases the risk of infestation among individuals in these environments. Thus, widespread usage of drugs among the aforementioned scenario will spur the market growth.
 

Lice treatment refers to the process of eliminating infestations of lice, which are parasitic insects that commonly affect humans and other mammals. The goal of lice treatment is to eradicate both the adult lice and their eggs from the affected individual's body or environment, thereby stopping the infestation and preventing its spread to others. Further, the lice treatment methods typically involve the use of medicated shampoos, lotions, or sprays containing insecticides or other active ingredients that kill lice.
 

Lice Treatment Market Trends

• The growth of the market is significantly propelled by the easy availability of lice treatment products, which are accessible through various retail channels such as pharmacies, supermarkets, and online platforms. This widespread availability ensures that individuals can quickly and conveniently obtain treatment options when faced with lice infestations.
   
• Further, with over the counter (OTC) drugs and products readily accessible without the need for a prescription, consumers are empowered to initiate treatment promptly at the first indication of an infestation. This timely intervention is crucial for effectively managing lice infestations and preventing their spread to others, thereby augmenting the market expansion.
   

Lice Treatment Market Analysis

The market based on product type is segmented into OTC products and prescription medications. The OTC products segment accounted for majority of market share of 62.6% in 2023.
 

• OTC lice treatment products offer convenience and accessibility, allowing consumers to purchase them easily from pharmacies, supermarkets, and online retailers. The availability of OTC products without the need for a prescription enables individuals to initiate treatment promptly at the first sign of a lice infestation. Hence, the segment's growth has been impacted by rising environmental concerns along with consumer demand for non-toxic, eco-friendly products, thereby fostering the segment growth.

Learn more about the key segments shaping this market

Download Free PDF

The lice treatment market based on type is classified into branded and generic. The generic segment dominated the market and is expected to reach USD 1 billion by 2032.
 

• Generic lice treatment products are typically more affordable than their branded counterparts, making them an attractive option for consumers seeking cost-effective solutions. Also, as healthcare costs continue to rise, affordability becomes a significant consideration for individuals, resulting to increase in product demand, thereby supplementing the market demand.
   

Based on route of administration, the lice treatment market is classified into oral and topical. The topical segment dominated the market and is expected to exhibit 6.3% CAGR between 2024 – 2032.
 

• Ongoing research and development focused on creating novel formulations for topical lice treatments especially for easier to apply, improved efficacy, and provide longer-lasting effects will spur the market growth.
   
• Also, presence of several companies and their involvement in developing topical lice product that are easy to use and convenient for consumers will further propel the segmental growth.
   

The lice treatment market based on condition is segmented into pediculosis capitis, pediculosis corporis, and pediculosis pubis. The pediculosis capitis segment accounted for market share of 43.7% in 2023.
 

• Integrated approaches to the management of pediculosis capitis are gaining popularity. These approaches combine various treatment modalities, such as topical treatments, environmental management, and education programs, to achieve better control and prevention of head lice infestations will foster the market growth.
   
• Also, changes in hygiene practices especially while travelling and socioeconomic factors may also influence the prevalence of head lice infestations in certain communities. Thus, availability of different treatment product in the market will augment the market growth.
   

The lice treatment market based on dosage form is segmented into tablets, shampoos, lotions, cream, and other dosage forms. The shampoos segment is expected to reach USD 704.8 million by end of 2032.
 

• Shampoo formulations are designed to offer convenience and ease of use, particularly for parents treating children with lice infestations. These shampoos are formulated to lather well and rinse out easily, minimizing the time and effort required for treatment. Therefore, manufacturers and healthcare providers are placing greater emphasis on therapeutic education to ensure proper and effective use of lice treatment shampoos. Thus, aforementioned factors associated with shampoo segment will foster the market growth.
   

By distribution channel, the lice treatment market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. The retail pharmacies is expected to show significant growth of 6.8% during the analysis period.
 

• One of the major factors contributing to the segmental growth include easy access to a large selection of over-the-counter medical supplies, including a choice of remedies for common ailments.
   
• Also, retail pharmacies are frequently the first choice for worried parents or anyone looking for practical solutions when it comes to treating lice. These pharmacies make it simple for clients to take care of this frequent problem by providing a wide range of lice treatment items, such as multiple shampoos, combs, and treatments. Thus, availability of different treatment products in the retail pharmacies will supplement the market growth.

North America lice treatment market accounted for USD 461.5 million market revenue in 2023 and is anticipated to grow at CAGR of 6.4% between 2024 – 2032 period.
 

• Presence of a larger infestation pool and an increasing children population are major factors contributing to the growth of the market. Also, manufacturers are expanding their product portfolios to offer a wide range of lice treatment options, including shampoos, lotions, sprays, and kits.
   
• Diverse product offerings cater to different preferences, needs, and age groups, driving market growth and consumer engagement. Thus, aforementioned factors are contributing to the growth of North America market.
   

Lice Treatment Market Share

The lice treatment industry is characterized by the presence of several key players offering innovative solutions. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.
 

Lice Treatment Market Companies

Prominent players operating in the lice treatment industry include:

• Alliance Pharma PLC
• Azurity Pharmaceuticals, Inc.
• Fleming Medical Ltd.
• Oystershell Consumer Health
• Parapro Pharmaceuticals
• Perrigo Company plc
• Prestige Consumer Healthcare Inc.
• Reckitt Benckiser Group plc
• Sanofi S.A.
• Thornton & Ross Ltd.
   

Lice Treatment Industry News:

• In October 2022, Alliance Pharmaceuticals, in partnership with South Florida Family Health and Research Centers, initiated a clinical trial to assess the safety and effectiveness of Vamousse Spray 'n' Go compared to a 1% Permethrin control shampoo for treating head lice. This clinical trial aim to provide valuable insights into the performance of Vamousse Spray 'n' Go in combating head lice infestations, offering a potential alternative or improvement over existing treatment options.
   
• In August 2021, ParaPRO, a specialty pharmaceutical company, announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, which became the first product approved by the U.S. Food and Drug Administration (FDA) for the treatment of scabies. The approval of Natroba for scabies treatment represents a notable advancement in the landscape of scabies therapy, providing a targeted topical therapy. This strategy strengthened the company’s product offerings.
   

The lice treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• OTC products
  • Permethrin
  • Pyrethrin
  • Other OTC products 
• Prescription medications
  • Ivermectin
  • Spinosad
  • Malathion
  • Other prescription medications

Market, By Type

• Branded
• Generic

Market, By Route of Administration

• Oral
• Topical

Market, By Condition

• Pediculosis capitis
• Pediculosis corporis
• Pediculosis pubis

Market, By Dosage Form

• Tablets
• Shampoos
• Lotions
• Cream
• Other dosage forms

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
• Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa